$SILO
Silo Pharma, Inc. Stock $silo

$silo Overview Financials Valuation SEC Filings Company Website

2023 Q1 Form 10-K Financial Statement

#000121390023022813 Filed on March 24, 2023

Income Statement

Concept	2023 Q1	2022 Q4	2022 Q3
Revenue	$64.39K	$18.03K	$18.03K
YoY Change	257.12%	0.0%	0.0%
Cost Of Revenue	$1.460K	$1.460K	$1.459K
YoY Change	0.0%	0.0%	-0.07%
Gross Profit	$16.57K	$16.57K	$16.57K
YoY Change	-0.02%	0.0%	-0.02%
Gross Profit Margin	25.73%	91.9%	91.88%
Selling, General & Admin	$64.97K	$1.039M	$60.34K
YoY Change	-82.61%	115.07%	-85.28%
% of Gross Profit	392.16%	6269.4%	364.25%
Research & Development	$202.9K	$634.7K	$375.8K
YoY Change	19.16%	33.35%	432.97%
% of Gross Profit	1224.88%	3830.3%	2268.47%
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses	$820.1K	$1.674M	$965.7K
YoY Change	50.79%	74.51%	100.98%
Operating Profit	-$803.5K	-$1.657M	-$949.2K
YoY Change	52.39%	75.82%	104.59%
Interest Expense	$1.655K	-$6.160K	-$34.09K
YoY Change	-101.03%	-94.63%	-100.49%
% of Operating Profit
Other Income/Expense, Net	-$102.9K	$280.00	-$34.09K
YoY Change	-220.04%
Pretax Income	-$906.4K	-$1.663M	-$983.2K
YoY Change	50.34%	57.31%	-115.15%
Income Tax	$906.4K	$0.00
% Of Pretax Income
Net Earnings	-$906.4K	-$1.663M	-$983.2K
YoY Change	50.05%	52.74%	-115.4%
Net Earnings / Revenue	-1407.71%	-9222.57%	-5453.39%
Basic Earnings Per Share	-$0.29		-$0.49
Diluted Earnings Per Share	-$0.29	-$0.52	-$0.49
COMMON SHARES
Basic Shares Outstanding	3.159M shares	3.139M shares	99.40M shares
Diluted Shares Outstanding	3.159M shares		2.001M shares

Balance Sheet

Concept	2023 Q1	2022 Q4	2022 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$10.68M	$11.37M	$12.33M
YoY Change	13.51%	10.85%	11.27%
Cash & Equivalents	$4.666M	$11.37M	$12.25M
Short-Term Investments	$6.017M	$3.120K	$77.94K
Other Short-Term Assets	$204.4K	$135.9K	$581.4K
YoY Change	-1.02%	-6.49%	163.55%
Inventory
Prepaid Expenses		$21.17K
Receivables
Other Receivables		$60.00K	$60.00K
Total Short-Term Assets	$10.95M	$11.57M	$12.91M
YoY Change	13.89%	11.24%	14.25%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments		$3.118K	$77.94K
YoY Change		-99.26%
Other Assets	$69.36K	$70.82K	$64.80K
YoY Change	97.05%	15.7%	130.44%
Total Long-Term Assets	$69.36K	$70.82K	$137.1K
YoY Change	-28.93%	-19.4%	55.57%
TOTAL ASSETS
Total Short-Term Assets	$10.95M	$11.57M	$12.91M
Total Long-Term Assets	$69.36K	$70.82K	$137.1K
Total Assets	$11.02M	$11.64M	$13.05M
YoY Change	13.46%	10.99%	14.57%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$660.3K	$364.2K	$223.7K
YoY Change	323.77%	-12.85%	5.85%
Accrued Expenses		$20.13K
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$0.00
YoY Change
Total Short-Term Liabilities	$732.4K	$436.3K	$312.2K
YoY Change	150.17%	-10.96%	10.16%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$847.8K	$865.8K	$883.8K
YoY Change	-7.84%	-7.69%	-7.54%
Total Long-Term Liabilities	$847.8K	$865.8K	$883.8K
YoY Change	-7.84%	-7.69%	-7.54%
TOTAL LIABILITIES
Total Short-Term Liabilities	$732.4K	$436.3K	$312.2K
Total Long-Term Liabilities	$847.8K	$865.8K	$883.8K
Total Liabilities	$1.580M	$1.302M	$1.196M
YoY Change	30.31%	-8.81%	-3.49%
SHAREHOLDERS EQUITY
Retained Earnings	-$8.078M	-$7.171M	-$5.508M
YoY Change		119.8%
Common Stock	$316.00	$316.00	$314.00
YoY Change		-96.8%
Preferred Stock		$17.51M
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$9.444M	$10.34M	$11.85M
YoY Change
Total Liabilities & Shareholders Equity	$11.02M	$11.64M	$13.05M
YoY Change	13.46%	10.99%	14.57%

Cashflow Statement

Concept	2023 Q1	2022 Q4	2022 Q3
OPERATING ACTIVITIES
Net Income	-$906.4K	-$1.663M	-$983.2K
YoY Change	50.05%	52.74%	-115.4%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities	-$692.7K	-$886.0K	-$1.422M
YoY Change	-12.23%	14.49%	114.5%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities	-$6.008M	$0.00	$0.00
YoY Change	-30141.7%	-100.0%	-100.0%
Cash From Investing Activities	-$6.008M	$0.00	$0.00
YoY Change	-30141.7%	-100.0%	-100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities		0.000	4.941M
YoY Change
NET CHANGE
Cash From Operating Activities	-$692.7K	-886.0K	-1.422M
Cash From Investing Activities	-$6.008M	0.000	0.000
Cash From Financing Activities		0.000	4.941M
Net Change In Cash	-$6.701M	-886.0K	3.519M
YoY Change		108.76%	-42.42%
FREE CASH FLOW
Cash From Operating Activities	-$692.7K	-$886.0K	-$1.422M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022	dei	Document Type DocumentType	10-K
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-12-31
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Entity File Number EntityFileNumber	001-41512
CY2022	dei	Entity Registrant Name EntityRegistrantName	SILO PHARMA, INC
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2022	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	27-3046338
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	560 Sylvan Avenue
CY2022	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 3160
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	Englewood Cliffs
CY2022	dei	Entity Address State Or Province EntityAddressStateOrProvince	NJ
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	07632
CY2022	dei	City Area Code CityAreaCode	(718)
CY2022	dei	Local Phone Number LocalPhoneNumber	400-9031
CY2022	dei	Security12b Title Security12bTitle	Common Stock, $0.0001 par value per share
CY2022	dei	Trading Symbol TradingSymbol	SILO
CY2022	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022	dei	Entity Small Business EntitySmallBusiness	true
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Public Float EntityPublicFloat	10083771	usd
CY2023Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	3158797	shares
CY2022	dei	Auditor Firm AuditorFirmId	106
CY2022	dei	Auditor Name AuditorName	Salberg & Company, P.A.
CY2022	dei	Auditor Location AuditorLocation	Boca Raton, Florida
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	11367034	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	9837001	usd
CY2022Q4	silo	Equity Investments At Cost EquityInvestmentsAtCost	3118	usd
CY2021Q4	silo	Equity Investments At Cost EquityInvestmentsAtCost	419995	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	135894	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	145324	usd
CY2022Q4	us-gaap	Interest Receivable Current InterestReceivableCurrent	6010	usd
CY2022Q4	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	66010	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	11572056	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	10402320	usd
CY2021Q4	us-gaap	Interest Receivable Noncurrent InterestReceivableNoncurrent	1210	usd
CY2021Q4	silo	Note Receivable Noncurrent Including Interest Receivable NoteReceivableNoncurrentIncludingInterestReceivable	61210	usd
CY2022Q4	us-gaap	Prepaid Expense Noncurrent PrepaidExpenseNoncurrent	70821	usd
CY2021Q4	us-gaap	Prepaid Expense Noncurrent PrepaidExpenseNoncurrent	26659	usd
CY2022Q4	us-gaap	Assets Assets	11642877	usd
CY2021Q4	us-gaap	Assets Assets	10490189	usd
CY2022Q4	us-gaap	Loans Payable Current LoansPayableCurrent	364216	usd
CY2021Q4	us-gaap	Loans Payable Current LoansPayableCurrent	417937	usd
CY2022Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	72102	usd
CY2021Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	72102	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	436318	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	490039	usd
CY2022Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	865782	usd
CY2021Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	937884	usd
CY2022Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	865782	usd
CY2021Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	937884	usd
CY2022Q4	us-gaap	Liabilities Liabilities	1302100	usd
CY2021Q4	us-gaap	Liabilities Liabilities	1427923	usd
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	3158797	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	3158797	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1972739	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1972739	shares
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	316	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	197	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	17511589	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	12324646	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-7171128	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-3262577	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	10340777	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	9062266	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	11642877	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	10490189	usd
CY2022	silo	License Fees LicenseFees	72102	usd
CY2021	silo	License Fees LicenseFees	71264	usd
CY2022	us-gaap	Cost Of Revenue CostOfRevenue	5838	usd
CY2021	us-gaap	Cost Of Revenue CostOfRevenue	5004	usd
CY2022	us-gaap	Gross Profit GrossProfit	66264	usd
CY2021	us-gaap	Gross Profit GrossProfit	66260	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	577651	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	395123	usd
CY2022	us-gaap	Professional Fees ProfessionalFees	1496687	usd
CY2021	us-gaap	Professional Fees ProfessionalFees	1598367	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1286434	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	693910	usd
CY2022	us-gaap	General Insurance Expense GeneralInsuranceExpense	125889	usd
CY2021	us-gaap	General Insurance Expense GeneralInsuranceExpense	108750	usd
CY2022	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	-20000	usd
CY2021	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	-148500	usd
CY2022	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	227259	usd
CY2021	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	162953	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	3693920	usd
CY2021	us-gaap	Operating Expenses OperatingExpenses	2810603	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-3627656	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-2744343	usd
CY2022	us-gaap	Interest And Dividend Income Operating InterestAndDividendIncomeOperating	72637	usd
CY2021	us-gaap	Interest And Dividend Income Operating InterestAndDividendIncomeOperating	1210	usd
CY2022	us-gaap	Other Income OtherIncome	85733	usd
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	19082	usd
CY2022	us-gaap	Interest Expense InterestExpense	2199	usd
CY2021	us-gaap	Interest Expense InterestExpense	3036	usd
CY2022	us-gaap	Gain Loss On Investments GainLossOnInvestments	-104700	usd
CY2021	us-gaap	Gain Loss On Investments GainLossOnInvestments	6660483	usd
CY2022	silo	Unrealized Gain Loss On Equity Investments UnrealizedGainLossOnEquityInvestments	-331203	usd
CY2021	silo	Unrealized Gain Loss On Equity Investments UnrealizedGainLossOnEquityInvestments	248588	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-279732	usd
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	6926327	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-3907388	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	4181984	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	24876	usd
CY2022	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-3907388	usd
CY2021	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	4157108	usd
CY2021	us-gaap	Discontinued Operation Gain Loss On Disposal Of Discontinued Operation Net Of Tax DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax	1553	usd
CY2022	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Before Income Tax DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax	-1163	usd
CY2021	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Before Income Tax DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax	-254920	usd
CY2022	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	-1163	usd
CY2021	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	-253367	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-3908551	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	3903741	usd
CY2021	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	1403997	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-3908551	usd
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	2499744	usd
CY2022	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-1.71
CY2021	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	1.45
CY2022	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-1.71
CY2021	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	1.43
CY2022	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	0
CY2021	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	-0.13
CY2022	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	0
CY2021	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	-0.13
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	2284240	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1897315	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	2284240	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1918444	shares
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	1280695	usd
CY2021	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	3794102	usd
CY2021	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	83728	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	3903741	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	9062266	usd
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	4940948	usd
CY2022	silo	Amortization Of Prepaid Stockbased Compensation AmortizationOfPrepaidStockbasedCompensation	111014	usd
CY2022	silo	Stock Issued During Period Value Common Shares Issued For Professional Fees StockIssuedDuringPeriodValueCommonSharesIssuedForProfessionalFees	135100	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-3908551	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	10340777	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-3908551	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	3903741	usd
CY2022	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	-20000	usd
CY2021	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	-148500	usd
CY2022	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	156047	usd
CY2021	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	83728	usd
CY2021	silo	Amortization Of Prepaid Stockbased Expense AmortizationOfPrepaidStockbasedExpense	107970	usd
CY2022	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-104700	usd
CY2021	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	6660483	usd
CY2022	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-331203	usd
CY2021	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	248588	usd
CY2022	silo	Equity Shares Earned For Services EquitySharesEarnedForServices	-85733	usd
CY2021	us-gaap	Gains Losses On Restructuring Of Debt GainsLossesOnRestructuringOfDebt	19082	usd
CY2021	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	1553	usd
CY2022	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-55335	usd
CY2021	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	38862	usd
CY2021	silo	Increase Decrease In Assets Of Discontinued Operation IncreaseDecreaseInAssetsOfDiscontinuedOperation	-24963	usd
CY2022	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	4800	usd
CY2021	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	1210	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-53721	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	291050	usd
CY2022	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-72102	usd
CY2021	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	478736	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3497622	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2278016	usd
CY2022	us-gaap	Proceeds From Sale Of Equity Method Investments ProceedsFromSaleOfEquityMethodInvestments	66707	usd
CY2021	us-gaap	Proceeds From Sale Of Equity Method Investments ProceedsFromSaleOfEquityMethodInvestments	7020526	usd
CY2021	us-gaap	Proceeds From Collection Of Notes Receivable ProceedsFromCollectionOfNotesReceivable	7500	usd
CY2022	silo	Collection On Note Receivable CollectionOnNoteReceivable	20000	usd
CY2021	silo	Collection On Note Receivable CollectionOnNoteReceivable	164500	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	86707	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	7192526	usd
CY2021	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	3794102	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	4940948	usd
CY2021	silo	Advance From A Related Party AdvanceFromARelatedParty	2366	usd
CY2021	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	2366	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	4940948	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	3794102	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	1530033	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	8708612	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	9837001	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1128389	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	11367034	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	9837001	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	2199	usd
CY2022	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	25159	usd
CY2021	silo	Increase In Equity Investments Recorded As Deferred Revenue Pursuant To A Patent License Agree IncreaseInEquityInvestmentsRecordedAsDeferredRevenuePursuantToAPatentLicenseAgree	531250	usd
CY2021	silo	Note Receivable Issued In Connection With Asset Purchase Agreement NoteReceivableIssuedInConnectionWithAssetPurchaseAgreement	60000	usd
CY2022	silo	Common Stock Issued For Future Services CommonStockIssuedForFutureServices	135100	usd
CY2021Q3	us-gaap	Supplemental Deferred Purchase Price SupplementalDeferredPurchasePrice	60000	usd
CY2021Q3	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	60000	usd
CY2021Q3	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.08	pure
CY2021Q3	us-gaap	Investment Maturity Date InvestmentMaturityDate	2023-10-01
CY2022	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	3908551	usd
CY2022	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	3497622	usd
CY2022Q4	us-gaap	Retained Earnings Unappropriated RetainedEarningsUnappropriated	7171128	usd
CY2022Q4	silo	Working Capital WorkingCapital	11135738	usd
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><b>Use of Estimates</b></p><p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><b> </b></p><p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate could change in the near term due to one or more future events. Accordingly, the actual results could differ significantly from estimates. Significant estimates during the years ended December 31, 2022 and 2021 include the collectability of notes receivable, the percentage of completion of research and development projects, valuation of equity investments, estimates of the deemed dividend, valuation allowances for deferred tax assets, the fair value of warrants issued with debt and for services, and the fair value of shares and stock options issued for services and in settlements.</p><p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><b> </b></p>
CY2022Q4	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000	usd
CY2022Q4	silo	Cash Spic Insured Amount CashSPICInsuredAmount	250000	usd
CY2022	us-gaap	Fdic Indemnification Asset Cash Payments Received FDICIndemnificationAssetCashPaymentsReceived	10868000	usd
CY2021	us-gaap	Fdic Indemnification Asset Cash Payments Received FDICIndemnificationAssetCashPaymentsReceived	9100000	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-3908551	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	135894	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	145324	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Noncurrent PrepaidExpenseAndOtherAssetsNoncurrent	70821	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Noncurrent PrepaidExpenseAndOtherAssetsNoncurrent	26659	usd
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	2499744	usd
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	0	usd
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	24876	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1286434	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	693910	usd
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	433429	shares
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	368213	shares
CY2022	us-gaap	Net Income Loss From Continuing Operations Available To Common Shareholders Basic NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic	-3907388	usd
CY2021	us-gaap	Net Income Loss From Continuing Operations Available To Common Shareholders Basic NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic	2753111	usd
CY2022	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-1163	usd
CY2021	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-253367	usd
CY2022	us-gaap	Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation	2284447	shares
CY2021	us-gaap	Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation	1897315	shares
CY2022	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-1.71
CY2021	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	1.45
CY2022	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Basic Share DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare	0
CY2021	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Basic Share DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare	-0.13
CY2022	us-gaap	Net Income Loss From Continuing Operations Available To Common Shareholders Diluted NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersDiluted	-3907388	usd
CY2021	us-gaap	Net Income Loss From Continuing Operations Available To Common Shareholders Diluted NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersDiluted	2753111	usd
CY2021	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-3036	usd
CY2022	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-3907388	usd
CY2021	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	2750075	usd
CY2022	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-1163	usd
CY2021	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-253367	usd
CY2022	us-gaap	Net Income Loss From Discontinued Operations Available To Common Shareholders Diluted NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersDiluted	-3908551	usd
CY2021	us-gaap	Net Income Loss From Discontinued Operations Available To Common Shareholders Diluted NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersDiluted	2496708	usd
CY2022	us-gaap	Weighted Average Basic Shares Outstanding Pro Forma WeightedAverageBasicSharesOutstandingProForma	2284240	shares
CY2021	us-gaap	Weighted Average Basic Shares Outstanding Pro Forma WeightedAverageBasicSharesOutstandingProForma	1897315	shares
CY2021	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	5996	shares
CY2021Q4	us-gaap	Preferred Stock Capital Shares Reserved For Future Issuance PreferredStockCapitalSharesReservedForFutureIssuance	15133	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	2284240	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1918444	shares
CY2022	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-1.71
CY2021	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	1.43
CY2022	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	0
CY2021	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	-0.13
CY2021Q4	us-gaap	Equity Method Investments EquityMethodInvestments	419995	usd
CY2022	silo	Additionsof Equity Securities AdditionsofEquitySecurities	85733	usd
CY2021	silo	Additionsof Equity Securities AdditionsofEquitySecurities	531250	usd
CY2022	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	171407	usd
CY2021	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	359843	usd
CY2022	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-331203	usd
CY2021	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	248588	usd
CY2022Q4	us-gaap	Equity Method Investments EquityMethodInvestments	3118	usd
CY2021Q4	us-gaap	Equity Method Investments EquityMethodInvestments	419995	usd
CY2021	silo	Net Realized Gainloss On Equity Investments NetRealizedGainlossOnEquityInvestments	6660483	usd
CY2021Q3	us-gaap	Supplemental Deferred Purchase Price SupplementalDeferredPurchasePrice	60000	usd
CY2021Q3	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	60000	usd
CY2021Q3	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.08	pure
CY2021Q3	us-gaap	Investment Maturity Date InvestmentMaturityDate	2023-10-01
CY2022Q4	us-gaap	Investment Owned Balance Principal Amount InvestmentOwnedBalancePrincipalAmount	60000	usd
CY2022Q4	us-gaap	Interest Receivable InterestReceivable	6010	usd
CY2022	us-gaap	Financing Receivables Before Allowance For Credit Loss Average Amount Outstanding FinancingReceivablesBeforeAllowanceForCreditLossAverageAmountOutstanding	66010	usd
CY2021Q4	us-gaap	Investment Owned Balance Principal Amount InvestmentOwnedBalancePrincipalAmount	60000	usd
CY2021Q4	us-gaap	Interest Receivable InterestReceivable	1210	usd
CY2021	us-gaap	Financing Receivables Before Allowance For Credit Loss Average Amount Outstanding FinancingReceivablesBeforeAllowanceForCreditLossAverageAmountOutstanding	61210	usd
CY2021Q3	us-gaap	Inventory Net InventoryNet	58447	usd
CY2021Q3	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Assets BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets	58447	usd
CY2021Q3	silo	Net Asset Of Nfid Business Disposed NetAssetOfNFIDBusinessDisposed	58447	usd
CY2021Q3	silo	Consideration In The Form Of A Note Receivable ConsiderationInTheFormOfANoteReceivable	60000	usd
CY2021Q3	us-gaap	Gain Loss On Sale Of Other Assets GainLossOnSaleOfOtherAssets	1553	usd
CY2021	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets	119405	usd
CY2022	us-gaap	Disposal Group Including Discontinued Operation Costs Of Goods Sold DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold	1079	usd
CY2021	us-gaap	Disposal Group Including Discontinued Operation Costs Of Goods Sold DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold	103824	usd
CY2022	us-gaap	Disposal Group Including Discontinued Operation Gross Profit Loss DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss	-1079	usd
CY2021	us-gaap	Disposal Group Including Discontinued Operation Gross Profit Loss DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss	15581	usd
CY2022	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	84	usd
CY2021	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	270501	usd
CY2021	us-gaap	Gain Loss On Sale Of Other Assets GainLossOnSaleOfOtherAssets	1553	usd
CY2022	us-gaap	Discontinued Operation Tax Effect Of Discontinued Operation DiscontinuedOperationTaxEffectOfDiscontinuedOperation	-1163	usd
CY2021	us-gaap	Discontinued Operation Tax Effect Of Discontinued Operation DiscontinuedOperationTaxEffectOfDiscontinuedOperation	-253367	usd
CY2022Q4	us-gaap	Notes Receivable Gross NotesReceivableGross	60000	usd
CY2021Q4	us-gaap	Notes Receivable Gross NotesReceivableGross	220000	usd
CY2021Q4	silo	Additional Notes Receivable In2021 AdditionalNotesReceivableIn2021	60000	usd
CY2021Q4	silo	Collections On Notes Receivables CollectionsOnNotesReceivables	164500	usd
CY2021Q4	us-gaap	Financing Receivable Allowance For Credit Losses FinancingReceivableAllowanceForCreditLosses	55500	usd
CY2022Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	60000	usd
CY2021Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	60000	usd
CY2022Q4	silo	Less Notes Receivable Net Current Portion LessNotesReceivableNetCurrentPortion	-60000	usd
CY2021Q4	us-gaap	Notes Receivable Net NotesReceivableNet	60000	usd
CY2018Q3	us-gaap	Derivative Maturity Dates DerivativeMaturityDates	2020-09-27
CY2018Q4	silo	Promissory Note Agreement PromissoryNoteAgreement	50000	usd
CY2022Q4	us-gaap	Derivative Fixed Interest Rate DerivativeFixedInterestRate	0.10	pure
CY2022	us-gaap	Debt Instrument Interest Rate Increase Decrease DebtInstrumentInterestRateIncreaseDecrease	0.18	pure
CY2020Q1	silo	Received Shares ReceivedShares	10420	shares
CY2020Q4	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	196500	usd
CY2020Q4	silo	Notes Receivable Net Amount NotesReceivableNetAmount	23500	usd
CY2021Q2	silo	Bad Debt Recovery Cash Payment BadDebtRecoveryCashPayment	the Company and the investor, entered into a settlement agreement whereby both parties agreed to settle the remaining balance of this note receivable which was previously written off in year 2020 for a total settlement amount of $196,000 to be paid as follows; (i) an initial payment of $46,000 upon execution of the settlement agreement and (ii) $10,000 per month for fifteen months.
CY2021Q4	silo	Notes Receivable Net Amount NotesReceivableNetAmount	23500	usd
CY2021	silo	Recovered Bad Debt RecoveredBadDebt	141000	usd
CY2021	us-gaap	Loans Receivable Held For Sale Reconciliation To Cash Flow Period Increase Decrease LoansReceivableHeldForSaleReconciliationToCashFlowPeriodIncreaseDecrease	196500	usd
CY2022Q4	us-gaap	Assets Needed For Immediate Settlement Aggregate Fair Value AssetsNeededForImmediateSettlementAggregateFairValue	20000	usd
CY2022	silo	Bad Debt Recovery Expense BadDebtRecoveryExpense	20000	usd
CY2021	silo	Bad Debt Recovery Expense BadDebtRecoveryExpense	141000	usd
CY2022	silo	Remains Collectible Settlement Agreement Amount Reserved RemainsCollectibleSettlementAgreementAmountReserved	35500	usd
CY2021	silo	Recovered Aggregate Bad Debt RecoveredAggregateBadDebt	7500	usd
CY2021	us-gaap	Allowance For Loan And Lease Loss Recovery Of Bad Debts AllowanceForLoanAndLeaseLossRecoveryOfBadDebts	7500	usd
CY2021Q3	silo	Promissory Note PromissoryNote	0.08	pure
CY2022Q3	us-gaap	Derivative Maturity Dates DerivativeMaturityDates	2023-10-01
CY2021	us-gaap	Debt Instrument Periodic Payment Principal DebtInstrumentPeriodicPaymentPrincipal	60000	usd
CY2021Q4	us-gaap	Interest Receivable InterestReceivable	1210	usd
CY2021	us-gaap	Payments To Acquire Receivables PaymentsToAcquireReceivables	61210	usd
CY2022	us-gaap	Debt Instrument Periodic Payment Principal DebtInstrumentPeriodicPaymentPrincipal	60000	usd
CY2022Q4	us-gaap	Interest Receivable InterestReceivable	6010	usd
CY2022	us-gaap	Payments To Acquire Receivables PaymentsToAcquireReceivables	66010	usd
CY2022Q4	us-gaap	Excess Stock Shares Authorized ExcessStockSharesAuthorized	505000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2021Q1	us-gaap	Preferred Stock Convertible Shares Issuable PreferredStockConvertibleSharesIssuable	4280	shares
CY2021Q2	us-gaap	Convertible Preferred Stock Shares Issued Upon Conversion ConvertiblePreferredStockSharesIssuedUponConversion	4049	shares
CY2022Q1	us-gaap	Convertible Preferred Stock Shares Issued Upon Conversion ConvertiblePreferredStockSharesIssuedUponConversion	227	shares
CY2022	silo	Warrants Term WarrantsTerm	P5Y
CY2022Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	15
CY2022	us-gaap	Preferred Stock Conversion Basis PreferredStockConversionBasis	The Series C Convertible preferred stock and the February Warrants each contain a beneficial ownership limitation that restricts each of the investor’s ability to exercise the February Warrants and convert the Series C Convertible preferred stock such that the number of shares of the Company common stock held by each of them and their affiliates after such conversion or exercise does not exceed 4.99% (or, at the election of the Investor, 9.99%) of the Company’s then issued and outstanding shares of common stock.
CY2022	silo	Investor Invested Amount Percentage InvestorInvestedAmountPercentage	0.50	pure
CY2022	us-gaap	Construction Contractor Liquidity Characteristic ConstructionContractorLiquidityCharacteristic	If the Company fails to file the Registration Statement or have it declared effective by the dates set forth above, amongst other things, the Company will be obligated to pay the investors damages in the amount of 1% of their subscription amount, per month, until such events are satisfied.
CY2022	silo	Placement Agent Warrants Description PlacementAgentWarrantsDescription	In addition, pursuant to the terms of the offering, the Company issued Bradley Woods & Co, Ltd. and Katalyst Securities LLC warrants (the “Placement Agent Warrants”) to purchase up to an aggregate of 57,013 shares of common stock, or 10% of the shares of common stock issuable upon conversion of the Series C Preferred Stock and February Warrant Shares sold in the offering. The Placement Agent Warrants are exercisable for a period of five years from the closing date of the offering at an exercise price of $17.50 per share, subject to adjustment.
CY2021Q2	silo	Conversion Of Series C Convertible Preferred Stock Into Common Stock Description ConversionOfSeriesCConvertiblePreferredStockIntoCommonStockDescription	the Company notified holders of its Series C Convertible Preferred Stock of its election to force the conversion to 4,049 shares of its Series C Convertible Preferred Stock into 269,900 shares of the Company’s common stock. As of December 31, 2021, there were 227 shares of the Company’s Series Convertible Preferred Stock issued and outstanding
CY2022Q3	silo	Public Offering Shares PublicOfferingShares	1000000	shares
CY2022Q3	silo	Public Offering Price Per Share PublicOfferingPricePerShare	5
CY2022Q3	silo	Purchase Of Additional Shares PurchaseOfAdditionalShares	150000	shares
CY2022Q3	silo	Purchase Of Additional Shares PurchaseOfAdditionalShares	150000	shares
CY2022Q3	us-gaap	Initial Offering Period InitialOfferingPeriod	the Company closed the Offering and issued the Shares for aggregate net proceeds of $4,940,948, after deducting underwriting discounts and commissions and offering expenses. The Company intends to use the net proceeds from the offering for research and development activities, sales and marketing, general working capital purposes, potential acquisitions of other companies, products or technologies, and to repay certain indebtedness. Concurrently with the closing of the Offering, the Company also issued warrants to purchase an aggregate of up to 57,500 shares of its common stock to the representative of the Underwriters or its designees, at an exercise price of $6.25 per share (the “Representative’s Warrants”). The Representative’s Warrants are exercisable beginning on March 25, 2023, and expire on September 26, 2027, pursuant to the terms and conditions of the Representative’s Warrants.
CY2022Q3	us-gaap	Stock Issued During Period Shares Restricted Stock Award Gross StockIssuedDuringPeriodSharesRestrictedStockAwardGross	20000	shares
CY2022Q3	us-gaap	Common Stocks Including Additional Paid In Capital CommonStocksIncludingAdditionalPaidInCapital	135100	usd
CY2022Q3	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	6.755
CY2022Q4	us-gaap	Accrued Professional Fees Current And Noncurrent AccruedProfessionalFeesCurrentAndNoncurrent	45033	usd
CY2022	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	90067	usd
CY2021Q4	us-gaap	Debt Instrument Maturity Date DebtInstrumentMaturityDate	2026-12-26
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Description ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription	pursuant to an Employment Agreement (see Note 9), an aggregate of 16,000 incentive stock options were issued under the 2020 Plan, to Dr. Kou, exercisable at $10.00 per share and expires on January 31, 2032. The stock options vest as follows: (i) 6,000 stock options upon issuance; (ii) 5,000 vests on October 31, 2022 and; (iii) 5,000 vests on October 31, 2023.
CY2021Q1	silo	Purchase Agreements Description PurchaseAgreementsDescription	the Company entered into pursuant to securities purchase agreements with certain investors pursuant to which it sold warrants to purchase up to 285,067 shares of the Company’s common stock and 4,276 shares of the Company’s Series C Convertible preferred stock. The February Warrants are exercisable for a period of five years from the date of issuance at an exercise price of $15.00 per share, subject to adjustment. If, after a period of 180 days after the date of issuance of the February Warrants, a registration statement covering the resale of the February Warrant Shares is not effective, the holders may exercise the February Warrants by means of a cashless exercise. In addition, pursuant to the terms of the offering, the Company issued the Placement Agent Warrants to purchase up to an aggregate of 57,013 shares of common stock to its placement agents, or 10% of the shares of common stock issuable upon conversion of the Series C preferred stock and February Warrant Shares sold in the offering. The Placement Agent Warrants are exercisable for a period of five years from the closing date of the offering at an exercise price of $17.50 per share, subject to adjustment (see Series C Convertible Preferred Stock Financing above). Such warrants issued to various investors and to the placement agents were recorded as additional paid in capital with an offsetting debit applied against additional paid in capital, thus these warrants have no further accounting effect within the equity section.
CY2022Q3	us-gaap	Initial Offering Period InitialOfferingPeriod	concurrently with the closing of the Offering as discussed above, the Company also issued warrants to purchase an aggregate of up to 57,500 shares of its common stock to the representative of the Underwriters or its designees, at an exercise price of $6.25 per share (the “Representative’s Warrants”). The Representative’s Warrants are exercisable beginning on March 25, 2023, and expire on September 26, 2027, pursuant to the terms and conditions of the Representative’s Warrants.
CY2022	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-820796	usd
CY2021	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	819786	usd
CY2022	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-254056	usd
CY2021	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	253743	usd
CY2022	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	133994	usd
CY2021	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	-20893	usd
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	940858	usd
CY2021	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-1027760	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	24876	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	1550388	usd
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	609530	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	1550388	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	609530	usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	1550388	usd
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	609530	usd
CY2022Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	5638000	usd
CY2018Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	5638000	usd
CY2022Q4	srt	Financing Receivable Before Allowance For Credit Loss To Total Percent FinancingReceivableBeforeAllowanceForCreditLossToTotalPercent	1	pure
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	0	usd
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	940858	usd
CY2020Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	152619	shares
CY2022Q4	us-gaap	Officers Compensation OfficersCompensation	350000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Bonuses DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses	100000	usd
CY2022Q3	us-gaap	Loans Payable LoansPayable	42000	usd
CY2022Q3	us-gaap	Officers Compensation OfficersCompensation	60000	usd
CY2022Q1	us-gaap	Accrued Bonuses Current And Noncurrent AccruedBonusesCurrentAndNoncurrent	30000	usd
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted	16000	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	10
CY2022Q1	us-gaap	Lease Expiration Date1 LeaseExpirationDate1	2032-01-31
CY2022Q1	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions	6000	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	5000	shares
CY2020Q3	silo	License Fee LicenseFee	10000	usd
CY2021Q1	silo	License Fee LicenseFee	10000	usd
CY2022	silo	Commercial Sale Term CommercialSaleTerm	P10Y
CY2022	silo	License Agreement Expire LicenseAgreementExpire	P15Y
CY2022	silo	Sublicense Income Receivable Percentage SublicenseIncomeReceivablePercentage	0.15	pure
CY2022	us-gaap	Payments For Fees PaymentsForFees	75000	usd
CY2022	silo	Due To Related Partie Current DueToRelatedPartieCurrent	25000	usd
CY2022Q1	us-gaap	Fees Paid On Acceptances Resold FeesPaidOnAcceptancesResold	50000	usd
CY2021Q1	silo	License Fee LicenseFee	25000	usd
CY2022Q1	silo	License Fee LicenseFee	50000	usd
CY2022Q1	us-gaap	Long Term Debt Term LongTermDebtTerm	P15Y
CY2022	silo	Schedule Of Milestone Payments ScheduleOfMilestonePayments	<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; border-bottom: Black 1.5pt solid">Milestone</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Payment</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: left">Filing of an Investigational New Drug (or any foreign equivalent) for a Licensed Product</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">50,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Dosing of first patient in a Phase 1 Clinical Trial of a Licensed Product</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">100,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Dosing of first patient in a Phase 2 Clinical Trial of a Licensed Product</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">250,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Receipt of New Drug Application (“NDA”) (or foreign equivalent) approval for a Licensed Product</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">500,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Achievement of First Commercial Sale of Licensed Product</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,000,000</td><td style="text-align: left"> </td></tr> </table><p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"> </p>
CY2022	silo	Sales Of Licensed Products Percentage SalesOfLicensedProductsPercentage	0.05	pure
CY2022	us-gaap	Sales Commissions And Fees SalesCommissionsAndFees	50000000	usd
CY2022	silo	Schedule Of Umb Minimum Royalty Payments ScheduleOfUMBMinimumRoyaltyPayments	<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Years</b></span></td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Minimum <br/> Annual <br/> Royalty</b></span></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 89%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior to First Commercial Sale</span></td> <td style="width: 1%"> </td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="width: 8%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-139; font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</span></td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; "> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Year of First Commercial Sale</span></td> <td> </td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-140; font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</span></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">First calendar year following the First Commercial Sale</span></td> <td> </td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">25,000</span></td> <td> </td></tr> <tr style="vertical-align: bottom; "> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Second calendar year following the First Commercial Sale</span></td> <td> </td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">25,000</span></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Third calendar year following the First Commercial Sale</span></td> <td> </td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100,000</span></td> <td> </td></tr> </table><p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt"> </p>
CY2022	silo	License Fee LicenseFee	828	usd
CY2021	silo	License Fee LicenseFee	628	usd
CY2021Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	838	usd
CY2021Q4	us-gaap	Prepaid Expense Other Noncurrent PrepaidExpenseOtherNoncurrent	11034	usd
CY2022Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	838	usd
CY2022Q4	us-gaap	Prepaid Expense Other Noncurrent PrepaidExpenseOtherNoncurrent	10196	usd
CY2022	silo	Nonrefundable Cash Payment NonrefundableCashPayment	500000	usd
CY2022	silo	Net Sale Percentage NetSalePercentage	0.02	pure
CY2022	silo	Licensor Share LicensorShare	500	shares
CY2022	silo	Aggregate Of Converted Shares AggregateOfConvertedShares	625000	shares
CY2021Q1	silo	Aggregate Of Converted Shares AggregateOfConvertedShares	625000	shares
CY2021Q1	silo	Licensor Share LicensorShare	500	shares
CY2021Q1	silo	Nonrefundable Cash Payment NonrefundableCashPayment	500000	usd
CY2021Q1	silo	Revenue Term RevenueTerm	P15Y
CY2021	silo	Number Of Voting Shares NumberOfVotingShares	20000	shares
CY2021Q4	us-gaap	Excess Of Replacement Or Current Costs Over Stated Lifo Value ExcessOfReplacementOrCurrentCostsOverStatedLIFOValue	1000	usd
CY2021	us-gaap	Common Stock Convertible Conversion Price Increase CommonStockConvertibleConversionPriceIncrease	0.8
CY2021Q2	us-gaap	Common Stock Dividends Shares CommonStockDividendsShares	625000	shares
CY2021Q2	us-gaap	Common Stock Dividends Per Share Cash Paid CommonStockDividendsPerShareCashPaid	0.85
CY2021Q2	silo	Trading Price TradingPrice	531250	usd
CY2021Q2	us-gaap	Equity Method Investments EquityMethodInvestments	531250	usd
CY2021Q2	us-gaap	Deferred Revenue DeferredRevenue	531250	usd
CY2022Q4	us-gaap	Deferred Revenue DeferredRevenue	1031250	usd
CY2022Q4	silo	Cash Received CashReceived	500000	usd
CY2022Q4	silo	Securities Received SecuritiesReceived	531250	usd
CY2022	silo	Revenue Term RevenueTerm	P15Y
CY2022	us-gaap	Deferred Revenue Revenue Recognized1 DeferredRevenueRevenueRecognized1	68750	usd
CY2021	us-gaap	Deferred Revenue Revenue Recognized1 DeferredRevenueRevenueRecognized1	68750	usd
CY2021	us-gaap	Recognition Of Deferred Revenue RecognitionOfDeferredRevenue	68750	usd
CY2021	silo	Deferred Revenue Longterm Portion Amounted DeferredRevenueLongtermPortionAmounted	893750	usd
CY2022	silo	Consideration Fee Payable Percentage ConsiderationFeePayablePercentage	1.10	pure
CY2022	silo	Upfront License Fees UpfrontLicenseFees	50000	usd
CY2022	silo	First Commercial Sale FirstCommercialSale	P10Y
CY2022	silo	Agreement Shall Expire AgreementShallExpire	P15Y
CY2021Q2	silo	Upfront License Fees UpfrontLicenseFees	50000	usd
CY2022	silo	Recognized Revenues RecognizedRevenues	3352	usd
CY2022	us-gaap	Recognition Of Deferred Revenue RecognitionOfDeferredRevenue	3352	usd
CY2022	silo	Deferred Revenue Longterm Portion Amounted DeferredRevenueLongtermPortionAmounted	40782	usd
CY2022Q4	us-gaap	Other Notes Payable OtherNotesPayable	81474	usd
CY2022	silo	Sponsored Study Agreement SponsoredStudyAgreement	40737	usd
CY2021Q1	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	40737	usd
CY2021Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	40737	usd
CY2021Q2	silo	Sublicense Amount Paid SublicenseAmountPaid	342850	usd
CY2022	silo	Schedule Of Shall Pay Umb ScheduleOfShallPayUMB	<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Payment</b></span></td> <td> </td> <td> </td> <td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 3%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td> <td style="width: 1%"> </td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">92,095</span></td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 83%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon execution of the July 2021 Sponsored Research Agreement</span></td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2</span></td> <td> </td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">92,095</span></td> <td> </td> <td> </td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Six months after the start of project work as outlined in the July 2021 Sponsored Research Agreement</span></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</span></td> <td> </td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">92,095</span></td> <td> </td> <td> </td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon completion of the project work as outlined in the July 2021 Sponsored Research Agreement</span></td></tr> </table><p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"> </p>
CY2021Q3	us-gaap	Short Term Lease Payments ShortTermLeasePayments	92095	usd
CY2022Q3	us-gaap	Short Term Lease Payments ShortTermLeasePayments	92095	usd
CY2022Q4	silo	Accounts Payable Related Partie Current AccountsPayableRelatedPartieCurrent	92095	usd
CY2022Q4	us-gaap	Restructuring And Related Cost Expected Cost Remaining1 RestructuringAndRelatedCostExpectedCostRemaining1	143607	usd
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	71804	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.70	pure
CY2022Q4	us-gaap	Legal Fees LegalFees	41306	usd
CY2022Q4	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	21172	usd
CY2022	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	33252	usd
CY2022Q4	silo	Operating Leases Future Minimum Payment Due In Two Years OperatingLeasesFutureMinimumPaymentDueInTwoYears	898967	usd
CY2022Q4	silo	Operating Leases Future Minimum Payment Due OperatingLeasesFutureMinimumPaymentDue	898967	usd
CY2022	silo	Payment Of University PaymentOfUniversity	5000	usd
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	25000	usd
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	5000	usd
CY2021Q4	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent		usd
CY2022Q4	silo	Note Receivable Noncurrent Including Interest Receivable NoteReceivableNoncurrentIncludingInterestReceivable		usd
CY2022Q4	silo	Convertible Preferred Stock Value Issued2 ConvertiblePreferredStockValueIssued2		usd
CY2021Q4	silo	Convertible Preferred Stock Value Issued2 ConvertiblePreferredStockValueIssued2		usd
CY2022Q4	silo	Convertible Preferred Stock Value Issued ConvertiblePreferredStockValueIssued		usd
CY2021Q4	silo	Convertible Preferred Stock Value Issued ConvertiblePreferredStockValueIssued		usd
CY2022Q4	silo	Convertible Preferred Stock Value Issued1 ConvertiblePreferredStockValueIssued1		usd
CY2021Q4	silo	Convertible Preferred Stock Value Issued1 ConvertiblePreferredStockValueIssued1		usd
CY2021	us-gaap	Other Income OtherIncome		usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
CY2022	us-gaap	Discontinued Operation Gain Loss On Disposal Of Discontinued Operation Net Of Tax DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax		usd
CY2022	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact		usd
CY2021	us-gaap	Stock And Warrants Issued During Period Value Preferred Stock And Warrants StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants		usd
CY2021	silo	Common Stock Issued For Conversion Of Series C Preferred Stock CommonStockIssuedForConversionOfSeriesCPreferredStock		usd
CY2022	silo	Common Stock Issued For Conversion Of Series C Preferred Stock CommonStockIssuedForConversionOfSeriesCPreferredStock		usd
CY2022	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross		usd
CY2022	silo	Amortization Of Prepaid Stockbased Expense AmortizationOfPrepaidStockbasedExpense		usd
CY2021	silo	Equity Shares Earned For Services EquitySharesEarnedForServices		usd
CY2022	us-gaap	Gains Losses On Restructuring Of Debt GainsLossesOnRestructuringOfDebt		usd
CY2022	silo	Increase Decrease In Assets Of Discontinued Operation IncreaseDecreaseInAssetsOfDiscontinuedOperation		usd
CY2022	us-gaap	Proceeds From Collection Of Notes Receivable ProceedsFromCollectionOfNotesReceivable		usd
CY2022	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock		usd
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		usd
CY2022	silo	Advance From A Related Party AdvanceFromARelatedParty		usd
CY2022	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt		usd
CY2021	us-gaap	Interest Paid Net InterestPaidNet		usd
CY2021	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2022	silo	Increase In Equity Investments Recorded As Deferred Revenue Pursuant To A Patent License Agree IncreaseInEquityInvestmentsRecordedAsDeferredRevenuePursuantToAPatentLicenseAgree		usd
CY2022	silo	Note Receivable Issued In Connection With Asset Purchase Agreement NoteReceivableIssuedInConnectionWithAssetPurchaseAgreement		usd
CY2021	silo	Common Stock Issued For Future Services CommonStockIssuedForFutureServices		usd
CY2022	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet		usd
CY2022	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised		shares
CY2022Q4	us-gaap	Preferred Stock Capital Shares Reserved For Future Issuance PreferredStockCapitalSharesReservedForFutureIssuance		shares
CY2020Q4	us-gaap	Equity Method Investments EquityMethodInvestments		usd
CY2021Q3	silo	Finance Lease Liabilities FinanceLeaseLiabilities		usd
CY2022	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets		usd
CY2022	us-gaap	Gain Loss On Sale Of Other Assets GainLossOnSaleOfOtherAssets		usd
CY2022Q4	silo	Additional Notes Receivable In2021 AdditionalNotesReceivableIn2021		usd
CY2022Q4	silo	Collections On Notes Receivables CollectionsOnNotesReceivables		usd
CY2022Q4	us-gaap	Financing Receivable Allowance For Credit Losses FinancingReceivableAllowanceForCreditLosses		usd
CY2021Q4	silo	Less Notes Receivable Net Current Portion LessNotesReceivableNetCurrentPortion		usd
CY2022Q4	us-gaap	Notes Receivable Net NotesReceivableNet		usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
CY2021Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0001514183
CY2022	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false

Files In Submission

Name	View Source	Status
0001213900-23-022813-index-headers.html	Edgar Link	pending
0001213900-23-022813-index.html	Edgar Link	pending
0001213900-23-022813.txt	Edgar Link	pending
0001213900-23-022813-xbrl.zip	Edgar Link	pending
f10k2022ex21-1_silopharma.htm	Edgar Link	pending
f10k2022ex31-1_silopharma.htm	Edgar Link	pending
f10k2022ex31-2_silopharma.htm	Edgar Link	pending
f10k2022ex32-1_silopharma.htm	Edgar Link	pending
f10k2022ex4-1_silopharma.htm	Edgar Link	pending
f10k2022_silopharma.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
image_001.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
f10k2022_silopharma_htm.xml	Edgar Link	completed
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
silo-20221231.xsd	Edgar Link	pending
silo-20221231_cal.xml	Edgar Link	unprocessable
silo-20221231_def.xml	Edgar Link	unprocessable
silo-20221231_lab.xml	Edgar Link	unprocessable
silo-20221231_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SILO
Silo Pharma, Inc. Stock $silo

2023 Q1 Form 10-K Financial Statement

#000121390023022813 Filed on March 24, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SILO Silo Pharma, Inc. Stock $silo

2023 Q1 Form 10-K Financial Statement

#000121390023022813 Filed on March 24, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SILO
Silo Pharma, Inc. Stock $silo